Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The MRL-lpr murine model of
systemic lupus erythematosus
(
SLE
) has provided many insights into the pathology of human
lupus
. The model is characterized by an age-dependent expansion of a Thy-1+ alpha beta/CD3+ CD4-, CD8- T-cell subset in the nodes and spleen. In this study, a lpr T-cell specific monoclonal antibody, Ye19.1, was found to bind to a 200 kDa cell surface molecule (termed LTA) which has a
phosphotyrosine phosphatase
(
PTPase
) enzymatic function. The significance of this marker in the development of autoimmune pathology in MRL/lpr mice was also demonstrated; treatment of MRL-lpr mice with the Ye19.1 Ab was shown to retard the development of the autoimmune syndrome and to restore the T cell-dependent immune response to ovalbumin.
...
PMID:Alleviation of autoimmune disease in MRL-lpr mice by administration of Ye19.1, a monoclonal specific for the lpr T cell antigen, LTA. 179 25
To disclose the mechanism of aberrant function of peripheral blood lymphocytes (PBL) in
SLE
, we focused on the catalytic function of CD45, and determined the CD45
PTPase
activity in
SLE
patients. The sample population consisted of 32
SLE
patients with different disease activity.
PTPase
activity of cell lysates immunoprecipitated by anti-CD45 MoAb was assayed against phosphotyrosine analogue PNPP, followed by measuring the release of para-nitro phenol at 410 nm. CD45
PTPase
activity of PBL was significantly decreased in
SLE
patients, compared with that of normal controls and patients with systemic sclerosis (964 +/- 265, 1202 +/- 172, 1210 +/- 125, respectively;
SLE
versus normal, P<0.05). It was correlated with
SLE
Disease Activity Index (SLEDAI) score (r = 0.597, P = 0.0006), but not with the dose of prednisolone (r = 0.214, P = 0.2657), indicating that CD45
PTPase
activity became reduced when the disease was active, but it was not affected by prednisolone. Moreover, it was not corrected by in vitro culture with or without stimulation. The expression of CD45 on PBL was comparable between normal and
SLE
, raising a possibility that it may be due to aberrant regulation of catalytic function of CD45 in
SLE
. Given the evidence that tyrosine phosphorylation of cellular proteins by tyrosine kinases and phosphatases is one of the key biochemical events in the signal transduction pathway, the decreased CD45
PTPase
activity in
SLE
may account for the defective signal transduction via TCR/CD3, leading to dysregulated effector function of the lymphocytes.
...
PMID:Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE). 921 19
The red cell acid phosphatase (ACP1) gene, which encodes a low-molecular-weight
phosphotyrosine phosphatase
, has been suggested as a common genetic factor of autoimmunity. In the present study, we aim to investigate the possible association of ACP1 with the susceptibility of
systemic lupus erythematosus
(
SLE
). A total of 1,546
SLE
patients and 1,947 healthy individuals from 4 Caucasians populations were included in the present study. Four single-nucleotide polymorphisms (SNPs) were genotyped in this study: rs10167992, rs11553742, rs7576247, and rs3828329. ACP1*A, ACP1*B, and ACP1*C codominant ACP1 alleles were determined using 2 of the SNPs and analyzed. After the meta-analysis test was performed, a significant association of rs11553742*T was observed (p(pooled) = 0.005, odds ratios = 1.37 [1.10-1.70]), retaining significance after multiple testing was applied (p(FDR) = 0.019). Our data indicate for first time the association of rs11553742*T with increased susceptibility in
SLE
patients.
...
PMID:Novel association of acid phosphatase locus 1*C allele with systemic lupus erythematosus. 2206 83